Via American Action News:

The Chinese Communist Party’s bellicose rhetoric has reached new heights in its disinformation campaign on what caused the Wuhan coronavirus to spread.

Beijing is now threatening to disrupt the supply of pharmaceutical products it exports to the United States and plunge America into “the mighty sea of coronavirus.”

In response, Sen. Tom Cotton (R-AK) and Rep. Mike Gallagher (R-WI) introduced a bill to slash our dependence on China.
Fox News’ Tyler Olson reports:

“The Chinese Communist Party threatened to cut off America’s access to vital drugs in the midst of a pandemic caused by its own failures,” Cotton said in a statement announcing the bill. “It’s time to pull America’s supply chains for life-saving medicine out of China and make the CCP pay for contributing to this global emergency.”

A release announcing the bill says it would task an FDA registry with tracking drug ingredients, ban the federal government from buying drugs with a supply chain that originates in China, require drugs to be labeled with the name of the country where they came from and provide benefits to manufacturers who make their drugs or medical equipment in the U.S. The bill would go into effect in 2022.


“The Chinese Communist Party’s outrageous threats to withhold lifesaving drugs from the U.S. endangers public health and should open our eyes to our dangerous over-reliance on China in our medical supply chain,” Gallagher said. “This is a national security imperative that to many Americans, is a matter of life and death. It’s past time for us to develop an aggressive plan to move critical pharmaceutical supply chains away from China.”

Currently, most drug components used in the United States are made internationally, and that supply is largely in China. The communist nation supplies between 80 percent and 90 percent of American antibiotics and 70 percent of acetaminophen used in the United States, according to Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations.

Notify of
Inline Feedbacks
View all comments